Paraoxonase (PON1) 55 Polymorphism and Association with Systemic Lupus Erythematosus

Fariborz Bahrehmand; Asad Vaisi-Raygani; Reza Ahmadi; Amir Kiani; Zohreh Rahimi; Heidar Tavilani; Tayebeh Pourmotabbed

Paraoxonase (PON1) 55 Polymorphism and Association with Systemic Lupus Erythematosus

Abstract

Paraoxonase-1 (PON1) is a serum HDL-bound enzyme that hydrolyzes a number of aromatic carboxylic acid esters including lipid peroxides, preventing LDL oxidation. Systemic lupus erythematosus (SLE) patients are at greater risk of oxidative stress, which is associated with abnormal plasma lipid metabolism. In this study, association of PON-55 polymorphism with serum arylesterase (ARE) activities, malondialdehyde (MDA), neopterin, lipids and lipoproteins levels in SLE patients and the development of hypertension was investigated. The present case-control study consisted of 109 SLE patients with and without high blood pressure (BP) and 103 healthy controls from the population in the west of Iran. PON-55 Met<Leu polymorphism was detected by restriction fragment length polymorphism (PCR-RFLP), serum ARE activity, MDA, neoptrin, lipid and apolipoprotein levels were determined by spectrophotometery and HPLC and enzyme assay, respectively. The presence of PON-55 M/M genotype was found to be associated with SLE and the development of high BP. The SLE patients with PON-M (M/L+M/M) allele had significantly lower serum ARE activity, but higher neoptrin and LDL-C than the carriers of corresponding genotypes in control group. The ARE activity was positively correlated with HDL-C and negatively correlated with LDL-C and MDA levels in SLE patients. Whereas, in SLE patients with high BP, ARE activity was only found to be negatively correlated with MDA concentration. These data suggest that PON-55 M/M genotype is a risk factor for SLE. The carriers of this allele have high levels of MDA, neopterin and LDL-C, thus, they are more likely to develop hypertension.

1. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, et al. Human paraoxonase-3 is an HDL associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001; 21(4): 542–7.
2. Blatter Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguol P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997; 99(1):62-6.
3. Aviram M. Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today 1999; 5(9):66–78.
4. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic Biol Med 2004; 37:1317–23.
5. Pfohl M, Koch M, Enderle MD, Ku¨hn R, Fu¨llhase J, Karsch KR, et al. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes.1999; 48(3):623–7.
6. Koubaa N, Nakbi A, Hammami S, Attia N, Mehri S,Hamda K, et al. Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin Biochem 2009; 42(9):771–6.
7. Tripi LM, Manzi S, Chen Q, Kenney M, Shaw P.Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum 2006; 54(6):1928-39.
8. Dasgupta S, Demirci FY, Dressen AS, Kao AH, Rhew EY, Ramsey-Goldman R, et al. Association analysis of PON2 genetic variants with serum paraoxonase activity and systemic lupus erythematosus. Med Genet 2011; 12:7.
9. Kiss E, Seres I, Tarr T, Kocsis Z, Szegedi G, Paragh G.Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1108:83-91.
10. Vaisi-Raygani A, Ghaneialvar H, Rahimi Z, Tavilani H,Pourmotabbed T, Shakiba E, et al. Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease. Mol Biol Rep 2011; 38(8):5421-8.
11. Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Taheri M, Bardestani GR, et al. The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis. Genet Mol Res 2010; 9(3):1735-41.
12. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007; 369(9561):587-96.
13. Farhey Y, Hess EV. Accelerated atherosclerosis and coronary disease in SLE. Lupus 1997; 6(7):572-7.
14. Gaffney PM, Ortmann WA, Selby SA, Shark KB, Ockenden TC, Rohlf KE, et al. Genome screening in human systemic lupus erythematosus: results from a second Minnesota cohort and combined analyses of 187 sib-pair families. Am J Hum Genet 2000; 66(2):547–56.
15. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42(2):338-46.
16. Plazak W, Gryga K, Dziedzic H, Tomkiewicz-Pajak L, Konieczynska M, Podolec P, et al. Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, doublemasked, placebo-controlled study. Arthritis Res Ther 2011; 13(4):R117.
17. Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104(16):1887–93.
18. Bahremand F, Vaisi-Raygani A, Kiani A, Rahimi Z, Tavilani H, Navabi SJ, et al. Matrix metalloproteinase-2 functional promoter polymorphism G1575A is associated with elevated circulatory MMP-2 levels and increased risk of cardiovascular disease in systemic lupus erythematosus patients. Lupus 2012; 21(6):616-24.
19. Kiss E, Seres I, Zsolt K, Tarr T, Csípo I, Szegedi G, et al. [Analysis of paraoxonase activity and lipid profile in lupus patients]. Orv Hetil 2005; 146(47):2395-402.
20. Tewthanom K, Janwityanuchit S, Totemchockchyakarn K,Panomvana D. Correlation of lipid peroxidation and glutathione levels with severity of systemic lupus erythematosus: a pilot study from single center. J Pharm Pharm Sci 2008; 11(3):30-4.
21. Ben Mansour R, Lassoued S, Elgaied A, Haddouk S,Marzouk S. Enhanced reactivity to malondialdehyde- modified proteins by systemic lupus erythematosus autoantibodies. Scand J Rheumatol 2010; 39(3):247-53.
22. Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 2010; 62(7):2064-72.
23. Alves JD, Grima B. Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis. Curr Rheumatol Rep 2003; 5(5):383-90.
24. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40(9):1725.
25. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39(3):363-9.
26. Hasselwander O,Savage D,Mc Master D,Loughrey C,Mcnamee P,Middleton D,et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in transplant recipient. Kidney int 1999; 56(1):289-98.
27. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism, Am J Hum Genet 1983; 35(6):1126–38.
28. Asefi M, Vaisi-Raygani A, Bahrehmand F, Kiani A, Rahimi Z, Nomani H, et al. Paraoxonase (PON1) 55 polymorphism, lipid profiles and psoriasis. Br J Dermatol 2012; 167(6):1279-86.
29. Raygani AV, Rahimi Z, Kharrazi H, Tavilani H, Pourmotaabed A. Association between apolipoprotein E polymorphism blood profiles lipids, lipoproteins and apolipoproteins with Alzheimer’s disease. Neurosci Lett 2006; 408(1):68–72.
30. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 1993; 3(1):73-6.
31. Batuca JR, Ames PR, Amaral M, Favas C, Isenberg DA, Delgado Alves J. Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48(1):26–31.
32. Hayem G, Nicaise-Roland P, Palazzo E, de Bandt M, Tubach F, Weber M, et al. Anti-oxidized low- densitylipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 2001; 10(5):346–51.
33. Ames PRJ, Alves J, Inanc M, Isenberg DA, Nourooz- Zadeh J. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology (Oxford) 1999; 38(6):529–34.
34. Vaisi-Raygani A, Rahimi Z, Tavilani H, Vaisi-Raygani H, Kiani A, Aminian M, et al. Synergism between paraoxonase Arg 192 and the angiotensin converting enzyme D allele is associated with severity of coronary artery disease. Mol Biol Rep 2012; 39(3):2723-31.
35. Vaisi-Raygani A, Ghaneialvar H, Rahimi Z, Nomani H, Saidi M, Bahrehmand F, et al. The angiotensin converting enzyme D allele is an independent risk factor for early onset coronary artery disease. Clin Biochem 2010;43(15):1189-94.
36. Vaisi-Raygani A, Rahimi Z, Nomani H, Tavilani H, Pourmotabbed T. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. Clin Biochem 2007;40(15):1150-6.
37. Kharrazi H, Vaisi Raygani A, Sabokroh AR, Pourmotabbed T. Association between apolipoprotein E polymorphism and coronary artery disease in the Kermanshah population in Iran. Clin Biochem 2006;39(6):613-6.
38. Van Lenten BJ, Wagner AC, Navab M, Fogelman AM.Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 2001;276(3):1923–9.
39. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349(25):2407–15.
40. Rho YH, Solus J, Raggi P, Oeser A, Gebretsadik T, Shintani A, et al. Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(4):535-41.

Files	XML PDF (157KB)
Issue	Vol 12, No 3 (2013)
Section	Articles
Keywords
Arylesterase activity Blood pressure Lipid profile Malondialdehyde Paraoxonase 55genotype Systemic lupus erythematosus

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Bahrehmand F, Vaisi-Raygani A, Ahmadi R, Kiani A, Rahimi Z, Tavilani H, Pourmotabbed T. Paraoxonase (PON1) 55 Polymorphism and Association with Systemic Lupus Erythematosus. Iran J Allergy Asthma Immunol. 1;12(3):211-219?.

Vancouver

Download Citation